Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [5]. Core Insights - The company has established a high self-sufficiency and synergistic integrated ecosystem in the electrolytic aluminum industry, focusing on green aluminum transformation and global market expansion, which enhances its risk resilience and performance stability [5]. - The company is positioned as the 12th largest electrolytic aluminum producer in China, with a production capacity of 788,100 tons per year, and is strategically located in Inner Mongolia [4][13]. - The global and domestic demand for electrolytic aluminum is expected to grow, driven by sectors such as new energy vehicles and high-end manufacturing, with a projected increase in global demand from 74 million tons in 2025 to 77 million tons in 2028 [4][36]. Summary by Sections Company Overview - The company was founded in 2012 in Hohhot, Inner Mongolia, focusing on the production of electrolytic aluminum and alumina, gradually building an integrated industrial layout [13]. - The company has seen rapid growth in revenue and net profit, with revenues of 13.49 billion, 13.81 billion, and 15.16 billion RMB from 2022 to 2024, and net profits of 880 million, 1 billion, and 2.06 billion RMB respectively [19][24]. Electrolytic Aluminum Business - The domestic supply of electrolytic aluminum is constrained by a production cap of approximately 45 million tons per year, leading to a tight supply-demand balance [36]. - The company’s electrolytic aluminum production capacity is 788,100 tons per year, with a high capacity utilization rate of over 95% [49][58]. - The average selling price of electrolytic aluminum has fluctuated, with prices of 17,572, 16,174, and 17,120 RMB per ton from 2022 to 2024, while production costs have decreased significantly [60][66]. Alumina Business - The company has a current alumina production capacity of 1.2 million tons in Shandong, with plans to enhance its supply capabilities through the construction of a 1.5 million ton per year aluminum hydroxide production facility [76][81]. - The global alumina demand is projected to grow from 142 million tons in 2025 to 149 million tons in 2028, with China being the largest consumer [71]. Global Expansion and Green Transformation - The company is initiating a global strategy by planning to invest in a 500,000 tons per year electrolytic aluminum project in Saudi Arabia, targeting markets in the Middle East, North Africa, and Europe [4][5]. - The company is also constructing a large-scale wind and solar power station in Inner Mongolia to increase its green energy ratio, which is expected to significantly reduce carbon emissions associated with aluminum production [4].

Investment Rating - The investment rating for ZTO Express is "Outperform the Market" [6] Core Viewpoints - The report emphasizes that ZTO Express has a significant competitive advantage, primarily due to its leading market share, superior network management capabilities, brand premium, stronger stability among franchisees, and robust financial strength [3][14] - In the short to medium term, ZTO is expected to maintain its "quantity and quality" strategy, which, along with price increases and reduced low-cost packages, will optimize the demand structure in the express delivery industry, leading to a continuous increase in market share [3] - In the long term, as the competitive landscape stabilizes, ZTO is likely to develop a diversified service system, enhancing its profitability [3] Summary by Relevant Sections Industry Development Review - The express delivery demand in China has transitioned from rapid growth to steady growth, with the volume expected to increase from 2.34 billion pieces in 2010 to 199 billion pieces by 2025, reflecting a compound annual growth rate (CAGR) of 34.5% [1][34] - The competitive landscape has returned to rationality, with price competition being controlled within reasonable limits due to policies aimed at high-quality development [1][52] Company Development Review - ZTO Express has distinguished itself in the competitive landscape through innovative models and strategic foresight, becoming the first private express company to open inter-provincial network buses in 2005 and implementing a paid delivery model in 2007 [2] - The company has consistently led in investments in resources such as trunk vehicles and automation equipment, establishing a virtuous cycle of scale, cost, profit, and quality [2] Financial Forecast and Valuation - The report projects ZTO Express's net profit for 2025-2027 to be 9.48 billion, 10.59 billion, and 11.78 billion yuan, with year-on-year growth rates of 7.5%, 11.7%, and 11.2% respectively [3][5] - The current stock price corresponds to a price-to-earnings (PE) ratio of 12X and 11X for 2026 and 2027, indicating that the stock is still at a low valuation level [3][6]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The demand for trendy toys is not a false need; entertainment is a necessity. The "Kidult" trend, driven by demographic changes, media evolution, and consumer psychology, is a long-term trend in the toy industry, exemplified by the increasing market share of companies targeting adult consumers [1][14] - The global entertainment and media industry is projected to reach approximately $3 trillion by 2024, indicating a growing market for diversified entertainment offerings [1][35] Supply-Side Growth Potential - Store Expansion: The company has significant room for growth in retail locations, with a projected increase in global retail stores from 571 in 2025, with a substantial portion located in China [2][58] - Increased Store Traffic: Domestic single-store membership is expected to rise from 145,000 to nearly 200,000, with the opening of the first U.S. store in September 2023 [2] - Higher Member Spending: The maturity of IPs is expected to drive up the average spending per member, as seen with the SKULLPANDA IP, where the cost to purchase all products increased significantly from 5,922 RMB in 2021 to 47,430 RMB in 2025 [2] Demand-Side Competitive Barriers - Artist Talent Barrier: The company has established partnerships with mature toy artists in Hong Kong, creating a long-term competitive advantage [3] - Marketing Resource Barrier: The company's business model relies on top-tier brand collaborations and celebrity endorsements, which are core competitive barriers [3] - User Data Asset Barrier: The company has strong control over user data and market feedback due to its direct sales channels, enhancing operational efficiency [3] Valuation Safety Margin - The company's valuation is expected to be significantly above 10X PE, given its growth stage and the rising cultural influence of China on the global stage [3] Profit Forecast, Valuation, and Rating - Revenue projections for 2025-2027 are 36.96 billion, 55.10 billion, and 67.74 billion RMB, with adjusted net profits of 12.38 billion, 17.35 billion, and 22.66 billion RMB, reflecting growth rates of 295.98%, 40.21%, and 30.59% respectively [4][7] - The target price is set at 359.72 HKD, based on a 25X PE for 2026 [4]

Investment Rating - The report maintains a "Buy" rating for Ping An Insurance, with a target price raised to HKD 90 based on a sum-of-the-parts (SOTP) valuation [1][4]. Core Insights - The report highlights that the fourth quarter earnings may see relief amid growth stock corrections, with expectations of a 12% year-on-year increase in group OPAT for 2025, reaching RMB 136 billion, and a 5.1% increase in net profit to RMB 133 billion [1][3]. - The insurance company is projected to achieve double-digit growth in NBV (New Business Value) in 2026, driven by strong first-year premium growth and stable profit margins [2][4]. Summary by Sections Financial Performance - For FY25, the net profit is expected to be RMB 162.5 billion, with EPS projected at RMB 7.52, reflecting a 5.1% year-on-year increase [5][13]. - The report provides a detailed financial summary, indicating a steady increase in net profit and EPS over the forecast period, with net profit reaching RMB 175.7 billion by FY27 [5][15]. Valuation Metrics - The target price of HKD 90 implies a valuation of 0.9 times the FY26E price-to-earnings ratio and 1.24 times the price-to-book ratio [4][14]. - The report employs a comprehensive valuation method, indicating a fair value for various segments, including life insurance and property & casualty insurance, contributing to the overall target price [4][14]. Business Growth Drivers - The report notes that the bank's insurance channel is expected to benefit from a shift in household deposits, with a projected 18% growth in NBV for FY26 [2][4]. - The strong performance in the insurance sector is supported by robust underwriting profits and improved investment service results, particularly in the context of a recovering capital market [1][3].

股票研究 /[Table_Date] 2026.01.23 [Table_Industry] 运输 | 风险提示。经济波动，地缘局势，制裁执行力度变化，安全事故等。 | | --- | | 财务摘要(百万人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 22,733 | 23,244 | 30,650 | 40,995 | 43,693 | | (+/-)% | 21.8% | 2.2% | 31.9% | 33.8% | 6.6% | | 毛利润 | 3,381 | 4,037 | 4,516 | 6,619 | 7,002 | | 净利润 | 132.1% | 19.4% | 11.9% | 46.6% | 5.8% | | (+/-)% | 0.62 | 0.74 | 0.83 | 1.21 | 1.28 | | PE | 9.6% | 11.3% | 9.9% | 13.5% | 13.3% | | PB | 23.08 | 19.33 | 17.28 | 11. ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2][5]. Core Insights - The company has established a high self-sufficiency and synergistic integrated ecosystem in the electrolytic aluminum industry, focusing on green aluminum transformation and global market expansion, which enhances its risk resilience and performance stability [5]. - The company is positioned as the 12th largest electrolytic aluminum producer in China, with a production capacity of 788,100 tons per year, and is strategically located in Inner Mongolia, benefiting from abundant coal resources [4][13][49]. - The global and domestic demand for electrolytic aluminum is expected to grow, driven by sectors such as new energy vehicles and high-end manufacturing, with a projected increase in global demand from 74 million tons in 2025 to 77 million tons in 2028 [4][36]. Summary by Sections Company Overview - The company was founded in 2012 in Hohhot, Inner Mongolia, focusing on the production of electrolytic aluminum and alumina, gradually building an integrated industrial layout [13]. - The company has seen rapid revenue growth, with revenues of 13.49 billion, 13.81 billion, and 15.16 billion RMB from 2022 to 2024, reflecting a CAGR of 6% [19]. Electrolytic Aluminum Business - The domestic supply of electrolytic aluminum is constrained by a production cap of approximately 45 million tons per year, leading to a tight supply-demand balance [36]. - The company’s electrolytic aluminum production capacity is 788,100 tons per year, with a high capacity utilization rate of over 95% [49][58]. - The average selling price of electrolytic aluminum has fluctuated, with prices of 17,572, 16,174, and 17,120 RMB per ton from 2022 to 2024, while production costs have decreased due to falling raw material prices [60][66]. Alumina Business - The company has a current alumina production capacity of 1.2 million tons in Shandong, with plans to enhance its supply capabilities through the construction of a 1.5 million ton per year hydroxide aluminum production facility [76][81]. - The global alumina demand is projected to grow from 142 million tons in 2025 to 149 million tons in 2028, with China being the largest consumer [71]. Global Expansion and Green Transformation - The company is initiating a global strategy by planning to invest in a 500,000 ton per year electrolytic aluminum project in Saudi Arabia, targeting markets in the Middle East, North Africa, and Europe [4][5]. - The company is also constructing a large-scale wind and solar power station in Inner Mongolia to increase its green energy ratio, which is expected to significantly reduce carbon emissions associated with aluminum production [4].

Investment Rating - The investment rating for TCL Electronics is "Buy" [5]. Core Insights - The company has exceeded its equity incentive targets for 2025, with a strategic cooperation memorandum signed with Sony, accelerating its high-end and global strategies [2]. - The forecasted adjusted net profit for 2025 is between HKD 23.3 billion and HKD 25.7 billion, representing a year-on-year increase of 45% to 60% [9]. - The company maintains a leading position in the television market, with a projected global shipment of 30.41 million units in 2025, a 5.4% increase year-on-year [9]. Financial Summary - **Revenue Forecast (in thousand HKD)**: - 2023A: 78,986 - 2024A: 99,322 (+26%) - 2025E: 115,807 (+17%) - 2026E: 131,717 (+14%) - 2027E: 147,177 (+12%) [4] - **Net Profit Forecast (in million HKD)**: - 2023A: 744 - 2024A: 1,759 (+137%) - 2025E: 2,448 (+39%) - 2026E: 2,849 (+16%) - 2027E: 3,279 (+15%) [4] - **Valuation Ratios**: - PE: 2025E at 12.59, 2026E at 10.82, 2027E at 9.40 [4]. - PB: 2025E at 1.65, 2026E at 1.50, 2027E at 1.36 [4]. Strategic Developments - TCL Electronics has signed a strategic cooperation memorandum with Sony to establish a joint venture for home entertainment business, with TCL holding 51% and Sony 49% [9]. - The new company will operate under the "Sony" and "BRAVIA" brands, expected to start operations by April 2027 [9].

Investment Rating - The report assigns a "Buy" rating for the company, Minhua Holdings [3][57]. Core Insights - Minhua Holdings is the global leader in functional sofas, with a strong presence in both domestic and international markets. The company has successfully transitioned from a traditional export-oriented business to a model that balances export manufacturing with domestic brand sales [5][8]. - Recent financial performance shows a mixed trend, with a projected revenue decline of 8.2% in FY2025, but a slight recovery in net profit expected in FY2026 [5][15]. - The company is experiencing positive changes in its business operations, particularly in e-commerce sales, which have rebounded by 13.6% in FY26H1, reversing previous declines [28][39]. Financial Data and Valuation - Revenue projections for FY2024 to FY2028 are as follows: - FY2024: 18,411 million HKD - FY2025: 16,903 million HKD (down 8%) - FY2026: 16,392 million HKD (down 3%) - FY2027: 16,757 million HKD (up 2%) - FY2028: 17,424 million HKD (up 4%) [5][54]. - Net profit projections are: - FY2024: 2,302 million HKD - FY2025: 2,063 million HKD (down 10%) - FY2026: 2,067 million HKD (up 0.2%) - FY2027: 2,120 million HKD (up 2.5%) - FY2028: 2,208 million HKD (up 4.1%) [5][54]. - The company maintains a dividend payout ratio of around 50%, with a projected dividend yield of approximately 5.7% based on FY26 earnings [57]. Business Operations - The company has a balanced revenue structure with approximately 59% from domestic sales and 41% from international sales as of FY26H1 [6][17]. - The domestic sales model primarily focuses on the Zhihua brand, with a significant portion of revenue coming from sofas and mattresses [8][17]. - The company is pursuing strategic acquisitions, such as the planned acquisition of Gainline Recline Intermediate Corp, to enhance its business layout and operational synergies [39][41]. Profitability and Margin Analysis - The company has demonstrated resilience in profitability, with a net profit margin of 12.2% in FY2025, slightly below the previous year's 12.5% [43][54]. - Despite a decrease in average selling prices, the gross margin has improved, indicating strong cost control capabilities [43][54]. Investment Recommendations - The report suggests that Minhua Holdings, as a leader in the functional sofa market, is well-positioned for growth, particularly with its manufacturing advantages and recovery in online sales [57]. - The projected earnings for FY2026 to FY2028 indicate a gradual recovery in net profit, with expected growth rates of 0.2%, 2.5%, and 4.1% respectively [54][57].

Investment Rating - The report assigns a "Buy" rating to Shanghai Baoji Pharmaceutical with a target price of HK$ 111.30 [2][6]. Core Insights - Shanghai Baoji Pharmaceutical (02659.HK) is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using synthetic biology technology, targeting complex diseases with limited treatment options [3][12]. - The company has established a product pipeline consisting of one approved drug and seven candidates in clinical stages, along with four preclinical assets [3][12]. - The company aims to address the pain points of traditional pharmaceuticals by producing biopharmaceuticals that can replace biochemical extraction products derived from animal organs, blood, or urine [5][12]. Business Overview - The company is currently focused on four strategic therapeutic areas: i) large-volume subcutaneous administration, ii) antibody-mediated autoimmune diseases, iii) assisted reproductive drugs, and iv) other recombinant bioproducts [3][12]. - The company has a clear commercialization model and timeline, expecting significant revenue contributions starting in 2026 from its core products KJ017 and SJ02, with KJ103 anticipated to contribute from 2027 [4][12]. Product Development - KJ017, a key product, is a highly glycosylated recombinant hyaluronidase designed for subcutaneous drug delivery, expected to receive NDA approval in Q1 2026 [8][22]. - KJ103, a recombinant IgG degrading enzyme, is the only product of its kind expected to be launched in China, targeting autoimmune diseases and transplant desensitization [8][31]. - SJ02, a long-acting recombinant FSH product, has been approved for marketing and is expected to significantly improve patient outcomes in assisted reproduction [39][40]. Financial Projections - The company forecasts revenues of HK$ 6.9 million in 2024, increasing to HK$ 530 million by 2027, with a gross margin projected to decline from 97.8% in 2024 to 82.7% in 2027 [6][10]. - The company is expected to incur net losses in the coming years, with projected losses of HK$ 160.4 million in 2024 and HK$ 30.8 million in 2027 [6][10]. Market Position - The company has a first-mover advantage in China for its core products, which have already been commercialized in some foreign markets, indicating a strong market demand [4][12]. - The company has established partnerships with other pharmaceutical and biotechnology firms to develop subcutaneous drug delivery solutions, enhancing its market presence [26][29].

Investment Rating - The report maintains a "Buy" rating for 德昌电机控股 (0179) [2][11] Core Views - The company has shown stable operations in the first three quarters of the 2025-2026 fiscal year, with future growth expected from its robotics and liquid cooling sectors [2][11] - Despite facing operational pressures in the Asia-Pacific region, the company is implementing vertical integration and increasing automation to enhance efficiency and reduce costs [11] - The company is well-positioned to leverage its deep technical expertise in motors to expand into humanoid robotics and liquid cooling solutions, which are anticipated to be significant growth areas [11] Financial Summary - Total revenue for the first three quarters of 2025-2026 was $2.73 billion, remaining flat year-on-year; automotive product revenue decreased by 2%, while industrial product revenue increased by 1% [11] - The company forecasts earnings per share (EPS) of $0.28 for 2025, $0.33 for 2026, and $0.36 for 2027, with a target price of HKD 52.80 based on a 24x PE ratio for the 2025 fiscal year [11][12] - Projected total revenues are $3.648 billion for 2025, $3.718 billion for 2026, $4.060 billion for 2027, and $4.436 billion for 2028, with net profits expected to be $263 million for 2025 and growing to $338 million by 2028 [10][12]